Physician profile
Scott Cooper
NPI 1821275900
$2,783.80
in general payments reported to CMS, 2019-2025
19 companies · $42.16 in 2025
The $42.16 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,647 · 2020: $366 · 2021: $318 · 2022: $43.85 · 2023: $209 · 2024: $158 · 2025: $42.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $1,463.01 | 2019 | |
| Ambu INC. | $571.35 | 2020-2021 | |
| Abbvie INC. | $171.12 | 2019-2024 | Skyrizi, Rinvoq, Humira |
| Apollo Endosurgery US INC | $145.19 | 2023 | Orbera Intragastric Balloon System |
| Allergan, INC. | $73.43 | 2019 | |
| Boston Scientific Corporation | $50.11 | 2021-2024 | Bionic Navigator |
| Takeda Pharmaceuticals U.S.A., INC. | $43.53 | 2022-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.61 | 2019 | |
| Intercept Pharmaceuticals, INC. | $28.53 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $27.56 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $27.19 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $23.74 | 2025 | Dupixent |
| Celgene Corporation | $21.68 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $18.74 | 2022 | |
| Janssen Biotech, INC. | $17.77 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.04 | 2020 | |
| Vivus LLC | $17.00 | 2021 | |
| Genzyme Corporation | $16.31 | 2024 | |
| Merck Sharp & Dohme LLC | $14.89 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.